Comparative Pharmacology
Head-to-head clinical analysis: TESTODERM TTS versus TREST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTODERM TTS versus TREST.
TESTODERM TTS vs TREST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone is an androgen receptor agonist. It binds to and activates androgen receptors, leading to changes in gene expression that promote the development and maintenance of male secondary sexual characteristics, anabolic effects, and spermatogenesis.
Mirtazapine is a tetracyclic antidepressant that acts as a potent antagonist of central α2-adrenergic autoreceptors and heteroreceptors, leading to increased norepinephrine and serotonin neurotransmission. It also antagonizes 5-HT2 and 5-HT3 receptors, with no significant effect on serotonin reuptake.
Apply 4 mg (one 4 mg/24 hr system) or 6 mg (one 6 mg/24 hr system) transdermally once daily, applied to clean, dry, intact skin on the back, abdomen, thighs, or upper arms. Rotate application sites with an interval of at least 7 days.
10-15 mg orally every 6 hours as needed for agitation in dementia; maximum 60 mg/day.
None Documented
None Documented
The terminal elimination half-life of testosterone administered transdermally is approximately 1.5–2 hours. This short half-life requires daily application of the patch to maintain therapeutic levels.
Terminal elimination half-life: 4–6 hours (clinically, dosing every 6–8 hours maintains therapeutic levels).
Testosterone is excreted primarily in the urine as glucuronide and sulfate conjugates (approximately 90%), with about 6% excreted in feces via bile. Less than 1% is excreted unchanged.
Renal: 80% unchanged; biliary/fecal: 10% as metabolites; 10% other.
Category C
Category C
Androgen
Androgen